These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 35851998)
1. Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis. Moein A; Lu T; Jönsson S; Ribbing J; Kassir N; Zhang W; Sperinde G; Zhang R; Tang M; Oh YS; Bruno R; Zhu R CPT Pharmacometrics Syst Pharmacol; 2022 Sep; 11(9):1244-1255. PubMed ID: 35851998 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis. Wei X; Gibiansky L; Wang Y; Fuh F; Erickson R; O'Byrne S; Tang MT J Clin Pharmacol; 2018 Mar; 58(3):386-398. PubMed ID: 29178491 [TBL] [Abstract][Full Text] [Related]
3. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S; Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038 [TBL] [Abstract][Full Text] [Related]
4. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG; Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037 [TBL] [Abstract][Full Text] [Related]
5. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ; Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039 [TBL] [Abstract][Full Text] [Related]
6. Etrolizumab for induction of remission in ulcerative colitis. Rosenfeld G; Parker CE; MacDonald JK; Bressler B Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011661. PubMed ID: 26630451 [TBL] [Abstract][Full Text] [Related]
7. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Vermeire S; O'Byrne S; Keir M; Williams M; Lu TT; Mansfield JC; Lamb CA; Feagan BG; Panes J; Salas A; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Tew GW; Luca D; Tang MT; Diehl L; Eastham-Anderson J; De Hertogh G; Perrier C; Egen JG; Kirby JA; van Assche G; Rutgeerts P Lancet; 2014 Jul; 384(9940):309-18. PubMed ID: 24814090 [TBL] [Abstract][Full Text] [Related]
8. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis. Rutgeerts PJ; Fedorak RN; Hommes DW; Sturm A; Baumgart DC; Bressler B; Schreiber S; Mansfield JC; Williams M; Tang M; Visich J; Wei X; Keir M; Luca D; Danilenko D; Egen J; O'Byrne S Gut; 2013 Aug; 62(8):1122-30. PubMed ID: 22717454 [TBL] [Abstract][Full Text] [Related]
9. Exposure-response relationships of etrolizumab in patients with moderately-to-severely active ulcerative colitis. Kassir N; Zhu R; Moein A; Langenhorst J; Ribbing J; Zhang R; Tang MT; Oh YS; Zhang W CPT Pharmacometrics Syst Pharmacol; 2022 Sep; 11(9):1234-1243. PubMed ID: 35789549 [TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Rosario M; Dirks NL; Gastonguay MR; Fasanmade AA; Wyant T; Parikh A; Sandborn WJ; Feagan BG; Reinisch W; Fox I Aliment Pharmacol Ther; 2015 Jul; 42(2):188-202. PubMed ID: 25996351 [TBL] [Abstract][Full Text] [Related]
11. Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis. Wei X; Kenny JR; Dickmann L; Maciuca R; Looney C; Tang MT J Clin Pharmacol; 2016 Jun; 56(6):693-704. PubMed ID: 26412221 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease: Results from a Phase 1 Randomized Trial. Zhang W; Scalori A; Fuh F; McBride J; She G; Kierkus J; Korczowksi B; Li R; Abouhossein M; Kadva A; Park KT; Tang MT Inflamm Bowel Dis; 2022 Sep; 28(9):1348-1356. PubMed ID: 34849918 [TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis. Adedokun OJ; Xu Z; Liao S; Strauss R; Reinisch W; Feagan BG; Sandborn WJ Clin Ther; 2020 Jan; 42(1):157-174.e4. PubMed ID: 31982148 [TBL] [Abstract][Full Text] [Related]
14. Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program. Sandborn WJ; Vermeire S; Tyrrell H; Hassanali A; Lacey S; Tole S; Tatro AR; Adv Ther; 2020 Jul; 37(7):3417-3431. PubMed ID: 32445184 [TBL] [Abstract][Full Text] [Related]
15. Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. Tew GW; Hackney JA; Gibbons D; Lamb CA; Luca D; Egen JG; Diehl L; Eastham Anderson J; Vermeire S; Mansfield JC; Feagan BG; Panes J; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Kirby JA; Irving PM; De Hertogh G; Van Assche GA; Rutgeerts P; O'Byrne S; Hayday A; Keir ME Gastroenterology; 2016 Feb; 150(2):477-87.e9. PubMed ID: 26522261 [TBL] [Abstract][Full Text] [Related]
16. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease. Tang MT; Keir ME; Erickson R; Stefanich EG; Fuh FK; Ramirez-Montagut T; McBride JM; Danilenko DM Aliment Pharmacol Ther; 2018 Jun; 47(11):1440-1452. PubMed ID: 29601644 [TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis. Xu Y; Adedokun OJ; Chan D; Hu C; Xu Z; Strauss RS; Hyams JS; Turner D; Zhou H J Clin Pharmacol; 2019 Apr; 59(4):590-604. PubMed ID: 30536638 [TBL] [Abstract][Full Text] [Related]
18. Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies. Chua L; Friedrich S; Zhang XC Clin Pharmacokinet; 2023 Oct; 62(10):1479-1491. PubMed ID: 37610533 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088 [TBL] [Abstract][Full Text] [Related]
20. Machine Learning-Based Quantification of Patient Factors Impacting Remission in Patients With Ulcerative Colitis: Insights from Etrolizumab Phase III Clinical Trials. Harun R; Lu J; Kassir N; Zhang W Clin Pharmacol Ther; 2024 Apr; 115(4):815-824. PubMed ID: 37828747 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]